SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
Company Announcements

SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends

SAGE Therapeutics ( (SAGE) ) has shared an announcement.

Biogen has informed Sage Therapeutics of its decision to terminate their collaboration on the SAGE-324 molecule, effective February 17, 2025, following negative results from a recent clinical study. Despite this, the partnership between the two companies persists for the development and commercialization of ZURZUVAE®, an FDA-approved treatment for postpartum depression. As a consequence of the termination, Biogen’s licenses related to the SAGE-324 molecule will expire, with Sage receiving perpetual rights to certain Biogen technologies for the molecule.

Find detailed analytics on SAGE stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskSAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures
TheFlySage Therapeutics price target lowered to $8 from $13 at Truist
TheFlySage Therapeutics price target lowered to $8 from $9 at Oppenheimer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App